Objective
Direct costs of brain disorders make up for 60% of the total costs – which EBC estimated at 800 bln€/year in Europe. At European level, this health budget far exceeds that of cardiovascular diseases, brain diseases and diabetes together. ALAMEDA will research, develop and exploit the next generation of personalized AI healthcare support systems that improve the rehabilitation treatment of Parkinson’s, Multiple Sclerosis, and Stroke (PMSS) patients. Stemming from very specific clinical use cases, ALAMEDA will develop user-friendly solutions that will be designed and evaluated on the principles of value-based health. The consortium brings together established medical research teams, AI researchers, medical software vendors and healthcare market experts to demonstrate AI-based personalised prediction, prevention, and intervention approach in three (3) real world pilots. Liaisons have been established with projects MULTI-ACT and IDEA-FAST and the carefully structured workplan, embodies an integrated and harmonized approach with active patients’ engagement towards meeting the ALAMEDA objectives and delivering market-relevant outcomes of significant exploitation potential.
Fields of science
Call for proposal
H2020-SC1-DTH-2020-1
See other projects for this call
Funding Scheme
RIA - Research and Innovation action
Coordinator
10682 Athina
Greece
Participants (14)
10561 Athina
N1 7GU London
20123 Milano
16149 Genova
060042 Bucharest
050098 Bucuresti
7491 Trondheim
2540 Luxembourg
08330 Premia De Mar
1040 Nicosia
15235 Vrilissia
1700 Nicosia
09128 Cagliari
57001 Thermi Thessaloniki
